International activity

“Indar” – is a very progressive, modern manufacturing, that reached the top in producing medicines. I’m assured that our countries will have long-lasting strategic partnership. Ukraine has unique technologies to be proud of. Indar’s research and development of human recombinant insulin is reason for pride of Ukrainians. I cordially hope that we’ll be able to implement these technologies in Brazil as soon as possible. When that will occur millions of Brazilians who suffer diabetes will be directed to Ukraine.”

Carlos Gadelia
Head of Science, Technology and Strategic Procurements Secretariat of the Ministry of Healthcare of FR Brazil

PrJSC “Indar” is the first in Ukraine to export pharmaceutical products with high value added cost – biotechnology products and technologies of their manufacturing.

In the framework of the agreement “Indar” supplies to Federative Republic Brazil finished dosage forms of insulin and also transfers proprietary manufacturing technology of recombinant insulin to Brazilian specialists. Currently negotiations regarding insulin manufacturing reached final stage and realization of the agreement – is a strategic task to both countries. After the project is finalized by Ukrainian side, Brazil will be able to reach “insulin independence” and will produce insulin (from active pharmaceutical ingredient to finished dosage forms).

During previous two years “Indar” has been actively increasing market share of the products in other countries. Our company was one of the first to receive National GMP certificate, has Brazilian GMP (ANVISA) and initiated the process of receiving EU GMP. Insulins of “Indar” are registered in Kazakhstan, Russian Federation, Moldova, Syrian Republic, Yemen Arab Republic, Jordan and Iraq; negotiations are conducted regarding marketing of insulins in MERCOSUR countries (MERCOSUR – the united market of South America countries that accept the GMP certificate of ANVISA).

We are working at tailor-made portfolio that would match market needs and meet criteria of finance effectiveness ensuring our partners’ success on the market.

“I’m thankful to the government of Ukraine and management of “Indar” for the efforts that they make for settlement of comprehensive Ukrainian-Brazilian partnership in the sphere of healthcare technologies exchange. Those perspectives that become available to our countries as a result of this partnership, can’t be overestimated. “Indar” – is a very progressive, modern manufacturing, that reached the top in producing medicines. I’m assured that our countries will have long-lasting strategic partnership.”

Carlos Gadelia
Head of Science, Technology and Strategic Procurements Secretariat of the Ministry of Healthcare of FR Brazil